What are the indications for giritinib?

Gilteritinib is an oral tyrosine kinase inhibitor used to treat a specific type of leukemia, namely FLT3 mutation-positive acute myeloid leukemia (AML). FLT3mutations are one of the most common types of mutations in AML patients and are often associated with poor prognosis and accelerated disease progression.

The indications of giritinib mainly include the following aspects:

1.Treatment of acute myeloid leukemia (AML): Giritinib is approved for the treatment of FLT3 mutation-positive relapsed or refractory AML. This type of AML is often insensitive to traditional chemotherapy and requires specific treatments.

2. Second-line treatment option: For those patients who have received first-line treatment (such as chemotherapy) but have failed to respond or have disease recurrence, giritinib provides an effective second-line treatment option.

3.Other uses in clinical trials: In addition to its approved indications, giritinib is also exploring its potential use in the treatment of other types of leukemia and malignant tumors in clinical trials. These trials may expand the indications for giritinib and benefit more patients.

In general, giritinib, as a targeted therapy for FLT3 mutation-positive AML, has important clinical significance in improving the prognosis and survival rate of patients with this disease. In the future, as the study of this drug in more types of leukemia and other malignant tumors deepens, its indications may be further expanded to provide effective treatment options for more patients.